Romosozumab (Evenity)
Canadian Journal of Health Technologies · 08.10.2026 · 6 (10)
DOI: 10.51731/cjht.2026.1534 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 08.10.2026. Verfasst von CDA-AMC.
Abstract (Originalsprache)
On July 16, 2026, the Formulary Management Expert Committee (FMEC) deliberated on a Request for Advice for the past romosozumab reimbursement recommendation for the treatment of osteoporosis. In this case, public drug plans were seeking clarification on the definition, interpretation, and/or meaning of “treatment naive” [from original source] that should be applied for reimbursement of romosozumab, as outlined in the reimbursement conditions from the Canadian Drug Expert Committee (CDEC) in 2021. FMEC recommends updating the initiation condition for the reimbursement of romosozumab, such that reimbursement would no longer be contingent upon the need for a patient to be treatment naive.
Zitieren
APA
CDA-AMC (2026). Romosozumab (Evenity). Canadian Journal of Health Technologies, 6(10). https://doi.org/10.51731/cjht.2026.1534
Vancouver
CDA-AMC. Romosozumab (Evenity). Canadian Journal of Health Technologies. 2026;6(10). doi:10.51731/cjht.2026.1534
BibTeX
@article{CDAAMC2026,
author = {CDA-AMC},
title = {Romosozumab (Evenity)},
journal = {Canadian Journal of Health Technologies},
year = {2026},
volume = {6},
number = {10},
doi = {10.51731/cjht.2026.1534}
}
EUVIMED